Quarter 2026/Q2
| Line item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| -Change in Other Current Liabilities | -$61,000.00 | -$103,000.00 | -$33,000.00 | $257,000.00 | -$4,000.00 |
| -Change in Other Current Assets | $74,000.00 | $126,000.00 | -$174,000.00 | -$167,000.00 | -$159,000.00 |
| -Change in Payables and Accrued Expense | $6.47M | -$7.89M | $6.80M | $2.78M | $4.90M |
| -Change in Prepaid Assets | $109,000.00 | -$562,000.00 | $869,000.00 | -$1.87M | $864,000.00 |
| -Change in Inventory | -$5.79M | -$4.88M | -$6.26M | -$2.95M | $0.00 |
| -Change in Receivables | -$45.34M | -$22.34M | -$3.26M | -$532,000.00 | $496,000.00 |
| Change in Working Capital | -$42.71M | -$38.03M | -$2.09M | $828,000.00 | $6.40M |
| Other Non-Cash Items | $361,000.00 | -$1.61M | -$453,000.00 | $72,000.00 | $0.00 |
| Depreciation & Depletion & Amortization | $1.10M | $1.10M | $1.14M | $803,000.00 | $630,000.00 |
| Net Income from Continuing Operations | $20.07M | -$7.93M | -$23.50M | -$146.34M | -$26.64M |
| Net cash flow from continuing operations | -$17.81M | -$43.83M | -$23.46M | -$29.07M | -$18.98M |
| Net Common Stock Issuance | $0.00 | $0.00 | $0.00 | -$1.30M | $0.00 |
| -Change In Other Working Capital | $1.82M | -$2.38M | -$25,000.00 | $3.31M | $305,000.00 |
| Net cash flow from investing | $26.69M | $20.97M | $39.87M | -$63.39M | $28.44M |
| Free Cash Flow | -$18.20M | -$44.09M | -$23.48M | -$29.46M | -$19.94M |
| Effect of Exchange Rate Changes | $1,000.00 | -$3,000.00 | $20,000.00 | $10,000.00 | $3,000.00 |
| Beginning Cash Balance | $7.48M | $30.23M | $14.32M | $13.76M | $6.06M |
| Net Change in Cash | $8.85M | -$22.75M | $15.89M | $552,000.00 | $7.70M |
| Ending Cash Balance | $16.33M | $7.48M | $30.23M | $14.32M | $13.76M |
| Net Other Financing Charges | -$1.35M | -$146,000.00 | $537,000.00 | $0.00 | -$1.84M |
| Proceeds from Stock Option Exercised | $1.32M | $255,000.00 | $140,000.00 | $839,000.00 | $73,000.00 |
| Net Cash Flow from Continuing Financing Activities | -$33,000.00 | $109,000.00 | -$514,000.00 | $93.01M | -$1.77M |
| Financing Cash Flow | -$33,000.00 | $109,000.00 | -$514,000.00 | $93.01M | -$1.77M |
| Net Investment Purchase and Sale | $27.08M | $21.23M | $39.88M | -$63.00M | $29.41M |
| Net PPE Purchase and Sale | -$392,000.00 | -$258,000.00 | -$18,000.00 | -$389,000.00 | -$966,000.00 |
| Net Cash Flow from Continuing Investing Activities | $26.69M | $20.97M | $39.87M | -$63.39M | $28.44M |
| Operating Cash Flow | -$17.81M | -$43.83M | -$23.46M | -$29.07M | -$18.98M |
| Deferred Tax | – | – | $0.00 | – | – |
| Gain/Loss from Continuing Operations | – | – | $0.00 | $111.50M | -$4.45M |
| Net Issuance Payments Of Debt | – | – | -$654,000.00 | – | – |
No comments yet — be the first to weigh in on PGEN.